Cited by 102Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and MutationsProtein Tyrosine Phosphatases

The DOI matches its Crossref record; 76 of the 79 references it cites were found in a registry or an index.

A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer

Open access

Vasan, Neil, Boyer, Julie L., Herbst, Roy S.·2014·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-13-1762PMC PMC5369356

Open this paper in CoChat — free account

Abstract

Of the numerous oncogenes implicated in human cancer, the most common and perhaps the most elusive to target pharmacologically is RAS. Since the discovery of RAS in the 1960s, numerous studies have elucidated the mechanism of activity, regulation, and intracellular trafficking of the RAS gene products, and of its regulatory pathways. These pathways yielded druggable targets, such as farnesyltransferase, during the 1980s to 1990s. Unfortunately, early clinical trials investigating farnesyltransferase inhibitors yielded disappointing results, and subsequent interest by pharmaceutical companies in targeting RAS waned. However, recent advances including the identification of novel regulatory enzymes (e.g., Rce1, Icmt, Pdeδ), siRNA-based synthetic lethality screens, and fragment-based small-molecule screens, have resulted in a “Ras renaissance,” signified by new Ras and Ras pathway–targeted therapies that have led to new clinical trials of patients with Ras-driven cancers. This review gives an overview of KRas signaling pathways with an emphasis on novel targets and targeted therapies, using non–small cell lung cancer as a case example. Clin Cancer Res; 20(15); 3921–30. ©2014 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-13-1762

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
ras GENES
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The GTPase superfamily: a conserved switch for diverse cell functions
Bourne, H. R., Sanders, D. A. R., & McCormick, F. P. (1990) · Nature · doi:10.1038/348125a0 · Cited by 2,336
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
GEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Winton, T. L., Livingston, R. B., Johnson, D. H., Rigas, J. R., Johnston, M., Butts, C. A., Cormier, Y. F., Goss, G., Inculet, R., Vallières, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043623 · Cited by 1,810
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789

Show all 79 references

Sorted by citations

Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras -driven cancers
Mayers, J. R., Torrence, M. E., Danai, L. V., Papagiannakopoulos, T., Davidson, S. M., Bauer, M. R., Lau, A. N., Ji, B. W., Dixit, P. D., Hosios, A. M., et al. (2016) · Science · doi:10.1126/science.aaf5171 · Cited by 582
Protein palmitoylation and cancer
Ko, P., & Dixon, S. J. (2018) · EMBO Reports · doi:10.15252/embr.201846666 · Cited by 442
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Zhu, C., Guan, X., Zhang, X., Luan, X., Song, Z., Cheng, X., Zhang, W., & Qin, J.-J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01629-2 · Cited by 231
Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung
Shim, H. S., Kenudson, M. M., Zheng, Z., Liebers, M. R., Cha, Y. J., Ho, Q. V., Onozato, M. L., Le, L. P., Heist, R. S., & Iafrate, A. J. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000579 · Cited by 203
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Adderley, H., Blackhall, F. H., & Lindsay, C. R. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.049 · Cited by 209
Mechanisms of Resistance to KRASG12C-Targeted Therapy
Akhave, N. S., Biter, A. B., & Hong, D. S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1616 · Cited by 156
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
Tomasini, P., Walia, P., Labbé, C., Jao, K., & Leighl, N. B. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0084 · Cited by 135
Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma
Ali, S. A., Justilien, V., Jamieson, L., Murray, N. R., & Fields, A. P. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.012 · Cited by 106
Kirsten Ras* oncogene: Significance of its discovery in human cancer research
Tsuchida, N., Murugan, A. K., & Grieco, M. (2016) · Oncotarget · doi:10.18632/oncotarget.8773 · Cited by 94
Nature and Nurture: What Determines Tumor Metabolic Phenotypes?
Mayers, J. R., & Heiden, M. G. V. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0165 · Cited by 86
New tricks for human farnesyltransferase inhibitor: cancer and beyond
Wang, J., Yao, X., & Huang, J. Y. (2017) · MedChemComm · doi:10.1039/c7md00030h · Cited by 73
Biosensors for the detection of lung cancer biomarkers: A review on biomarkers, transducing techniques and recent graphene-based implementations
Lin, L. P., & Tan, M. T. T. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115492 · Cited by 68
Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy
Alves, S., Castro, L., Fernandes, M. S., Francisco, R., Castro, P. J. T. D., Priault, M., Chaves, S. R., Moyer, M. P., Oliveíra, C., Seruca, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5021 · Cited by 64
mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer
Liang, S.-Q., Bührer, E. D., Berezowska, S., Marti, T. M., Xu, D., Froment, L., Yang, H., Hall, S. R. R., Vassella, E., Yang, Z., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0479-6 · Cited by 55
Epiregulin as a therapeutic target in non-small-cell lung cancer
Sunaga, N., & Kaira, K. (2015) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s60427 · Cited by 55
KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
Bhattacharya, S., Socinski, M. A., & Burns, T. F. (2015) · Clinical and Translational Medicine · doi:10.1186/s40169-015-0075-0 · Cited by 53
Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours
Yurugi, H., Marini, F., Weber, C., David, K. A., Zhao, Q., Binder, H., Désaubry, L., & Rajalingam, K. (2017) · Oncogene · doi:10.1038/onc.2017.93 · Cited by 49
KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer
Kang, Y. W., Lee, J. E., Jung, K. H., Son, M. K., Shin, S., Kim, S., Fang, Z., YAN, H. H., Park, J. H., Han, B., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.013 · Cited by 45
Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy
Klochkov, S. G., Евгеньевна, Н. М., Yarla, N. S., Parvathaneni, M., Sharma, B., Tarasov, V. V., Barreto, G. E., Бачурин, С. О., Ashraf, G. M., & Aliev, G. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.010 · Cited by 46
Rethinking Gamma-secretase Inhibitors for Treatment of Non–small-Cell Lung Cancer: Is Notch the Target?
Pine, S. R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1635 · Cited by 45
Inhibition of kras-derived exosomes downregulates immunosuppressive BACH2/GATA-3 expression via RIP-3 dependent necroptosis and miR-146/miR-210 modulation
Petanidis, S., Domvri, K., Porpodis, Κ., Anestakis, D., Freitag, L., Hohenforst‐Schmidt, W., Tsavlis, D., & Zarogoulidis, P. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109461 · Cited by 43
Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarcinoma
Kishikawa, S., Hayashi, T., Saito, T., Takamochi, K., Kohsaka, S., Sano, K., Sasahara, N., Sasa, K., Kurihara, T., Hara, K., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-00690-w · Cited by 42
miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway
Sun, W., Wei, P., Tian, Y., Zou, W., Liu, J., & Zu, Y. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495835 · Cited by 41
Clinicopathological, immunohistochemical, and mutational analyses of pulmonary enteric adenocarcinoma: usefulness of SATB2 and β -catenin immunostaining for differentiation from metastatic colorectal carcinoma
Matsushima, J., Yazawa, T., Suzuki, M., Takahashi, Y., Ota, S., Nakajima, T., Yoshino, I., Yokose, T., Inoue, T., Kawahara, K., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.04.006 · Cited by 41
Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells
Xie, C., Li, Y., Li, L.-L., Fan, X.-X., Wang, Y.-W., Wei, C.-L., Liu, L., Leung, E. L.-H., & Yao, X.-J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00823 · Cited by 40
KRAS driven expression signature has prognostic power superior to mutation status in non‐small cell lung cancer
Nagy, Á. M., Pongor, L. S., Szabó, A., Santarpía, M., & Győrffy, B. (2016) · International Journal of Cancer · doi:10.1002/ijc.30509 · Cited by 39
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies
Fang, B. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv090 · Cited by 37
Mutant KRAS and GNAS DNA Concentrations in Secretin-Stimulated Pancreatic Fluid Collected from the Pancreatic Duct and the Duodenal Lumen
Sadakari, Y., Kanda, M., Maitani, K., Borges, M. W., Canto, M. I., & Goggins, M. (2014) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2014.14 · Cited by 35
KIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer
Liu, Y., Yang, H., Cao, J., Jiang, Y., Hao, J., Xu, X., Cai, Y., & Wang, M. (2016) · Scientific Reports · doi:10.1038/srep24786 · Cited by 33
Farnesyl transferase inhibitor FTI-277 inhibits breast cell invasion and migration by blocking H-Ras activation
Lee, K. H., Koh, M., & Moon, A. (2016) · Oncology Letters · doi:10.3892/ol.2016.4837 · Cited by 33
Selumetinib for the treatment of non-small cell lung cancer
Casaluce, F., Sgambato, A., Maione, P., Sacco, P. C., Santabarbara, G., & Gridelli, C. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1351543 · Cited by 33
The Overexpression of FEN1 and RAD54B May Act as Independent Prognostic Factors of Lung Adenocarcinoma
Hwang, J., Sung, W., Tu, H., Hsieh, K., Yeh, C., Chen, C., Tai, H., Hsu, C., Shieh, G. S., Chang, J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139435 · Cited by 33
Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol
Xu, S., Law, B. Y. K., Mok, S. W. F., Leung, E. L., Fan, X., Coghi, P. S., Wu, J., Leung, C., Ma, D., Liu, L., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3644 · Cited by 32
(3 + 3) Annulation of Nitroallylic Acetates with Stabilized Sulfur Ylides for the Synthesis of 2-Aryl Terephthalates
Satham, L., & Namboothiri, I. N. N. (2018) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.8b00917 · Cited by 30
A three-dimensional cloth-based microfluidic label-free proximity hybridization-electrochemiluminescence biosensor for ultrasensitive detection of K-ras gene
Su, Y. L., Liang, Y., Wu, H., Jiang, J., Lai, W., & Zhang, C. (2019) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2019.126654 · Cited by 30
Role of chemokines in metastatic niche: new insights along with a diagnostic and prognostic approach
Rezaeeyan, H., Shirzad, R., McKee, T. D., & Saki, N. (2018) · Apmis · doi:10.1111/apm.12818 · Cited by 29
Targeting lung cancer through inhibition of checkpoint kinases
Syljuåsen, R. G., Hasvold, G., Hauge, S., & Helland, Å. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00070 · Cited by 29
From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers
Saliani, M., Jalal, R., & Ahmadian, M. R. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0530 · Cited by 27
Correlation of Histologic Subtypes and Molecular Alterations in Pulmonary Adenocarcinoma: Therapeutic and Prognostic Implications
Kim, J., Jang, S. J., Choi, C., & Ro, J. Y. (2016) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000121 · Cited by 27
mTOR in Lung Neoplasms
Krencz, I., Sebestyén, A. R., & Khoór, A. (2020) · Pathology & Oncology Research · doi:10.1007/s12253-020-00796-1 · Cited by 26
Dual Inhibition of GLUT1 and the ATR/CHK1 Kinase Axis Displays Synergistic Cytotoxicity in KRAS -Mutant Cancer Cells
Erber, J., Steiner, J. D., Isensee, J., Lobbes, L. A., Toschka, A., Beleggia, F., Schmitt, A., Kaiser, R. W. J., Siedek, F., ten Persigehl, T., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3959 · Cited by 27
A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer
Khadela, A. D., Postwala, H. I., Rana, D. K., Dave, H., Ranch, K. M., & Boddu, S. H. S. (2023) · Medical Oncology · doi:10.1007/s12032-023-02005-w · Cited by 24
Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs
Uitdehaag, J. C. M., de Roos, J. A. D. M., van Doornmalen, A. M., Prinsen, M. B. W., Spijkers-Hagelstein, J. A. P., de Vetter, J. R. F., de Man, J., Buijsman, R. C., & Zaman, G. J. R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125021 · Cited by 24
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma
Gristina, V., Mantia, M. L., Galvano, A., Cutaia, S., Barraco, N., Castiglia, M., Perez, A., Bono, M., Iacono, F., Greco, M., et al. (2021) · Journal of Molecular Pathology · doi:10.3390/jmp2020016 · Cited by 24
Inducing Oncoprotein Degradation to Improve Targeted Cancer Therapy
Ray, D., Cuneo, K. C., Rehemtulla, A., Lawrence, T. S., & Nyati, M. K. (2015) · Neoplasia · doi:10.1016/j.neo.2015.08.008 · Cited by 22
Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value
Wang, H., Schabath, M. B., Liu, Y., Stringfield, O., Balagurunathan, Y., Heine, J., Eschrich, S. A., Ye, Z., & Gillies, R. J. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.11.002 · Cited by 22
Independent and core pathways in oncogenic KRAS signaling
Nussinov, R., Tsai, C., & Jang, H. (2016) · Expert Review of Proteomics · doi:10.1080/14789450.2016.1209417 · Cited by 21
The Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma Progression
Dietrich, P., Hellerbrand, C., & Bosserhoff, A. (2019) · Cancers · doi:10.3390/cancers11030398 · Cited by 20
Association of Exosomal miR-210 with Signaling Pathways Implicated in Lung Cancer
Chen, Q. Y., & Xie, X. (2021) · Genes · doi:10.3390/genes12081248 · Cited by 20
Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling
Marín‐Ramos, N. I., Piñar, C., Vázquez‐Villa, H., Martín‐Fontecha, M., González, Á., Canales, Á., Algar, S., Mayo, P. P., Jiménez‐Barbero, J., Gajate, C., et al. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201604905 · Cited by 19
Connecting the dots: LncRNAs in the KRAS pathway and cancer
Maqbool, M., Hussain, M. S., Bisht, A. S., Kumari, A., Kamran, A., Sultana, A., Kumar, R., Khan, Y., & Gupta, G. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155570 · Cited by 19
Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer
Singh, K., Pruski, M. A., Polireddy, K., Jones, N. C., Chen, Q., Yao, J., Dar, W. A., McAllister, F. M., Ju, C., Eltzschig, H. K., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1031-z · Cited by 18
The Next Generation of KRAS Targeting: Reasons for Excitement and Concern
Akhave, N. S., Biter, A. B., & Hong, D. S. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0356 · Cited by 17
BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC
Jauset, T., Massó-Vallés, D., Martínez-Martín, S., Beaulieu, M.-È., Foradada, L., Fiorentino, F. P., Yokota, J., Haendler, B., Siegel, S., Whitfield, J. R., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24648 · Cited by 19
Inhibition of Stearoyl-CoA Desaturase 1 Potentiates Anti-tumor Activity of Amodiaquine in Non-small Cell Lung Cancer
Hu, X., Xiang, J., Li, Y., Yan, X., Xu, S., Gao, X., & Qiao, S. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00843 · Cited by 16
Targeting KRAS : Crossroads of Signaling and Immune Inhibition
Kato, S., Fujiwara, Y., & Hong, D. S. (2022) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-5 · Cited by 15
EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition
Rotella, V., Fornaro, L., Vasile, E., Tibaldi, C., Boldrini, L., Chella, A., D’Incecco, A., Cirigliano, G., Chioni, A., Lupi, C., et al. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/preaccept-1417843480141843 · Cited by 13
Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer
Huang, L., Li, M., Wang, D., He, J., Wu, W., Qiangfeng, Z., Li, J., Xiao, M., Hu, J., He, Y., et al. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.08.021 · Cited by 13
Non-small cell lung cancer biomarkers and targeted therapy - two faces of the same coin fostered by nanotechnology
Mendes, R. G. P. R., Carreira, B., Baptista, P. V., & Fernandes, A. R. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1159914 · Cited by 15
Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology
Bianconi, F., Baldelli, E., Luovini, V., Petricoin, E. F., Crinò, L., & Valigi, P. (2015) · BMC Systems Biology · doi:10.1186/s12918-015-0216-5 · Cited by 13
The Combination of Loss of ALDH1L1 Function and Phenformin Treatment Decreases Tumor Growth in KRAS-Driven Lung Cancer
Lee, S.-H., Jeon, Y., Kang, J. H., Jang, H., Lee, H., & Kim, S. (2020) · Cancers · doi:10.3390/cancers12061382 · Cited by 13
Dual inhibition of FOXM1 and its compensatory signaling pathway decreased the survival of ovarian cancer cells
Lee, D. W., Lee, W., Kwon, M., & Lee, H. N. (2020) · Oncology Reports · doi:10.3892/or.2020.7845 · Cited by 13
Advanced technologies for screening and identifying covalent inhibitors
Guo, Y., Wen, S., Tong, A., & Wang, Y. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117833 · Cited by 11
Interactive, integrated analysis of single-cell transcriptomic and phylogenetic data with PhyloVision
Jones, M. G., Rosen, Y., & Yosef, N. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100200 · Cited by 10
Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC
Steen, N. V. D., Mentens, Y., Ramael, M., León, L. G., Germonpré, P. R., Ferri, J., Gandara, D. R., Giovannetti, E., Peters, G. J., Pauwels, P., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.010 · Cited by 10
Current and Emerging Therapies for Targeting the ERK1/2 & PI3K Pathways in Cancer
Abizadeh, E., Berglas, E., Abizadeh, A., Glatman, J., Lavi, A. B., Spivak, M., Sapir, T., & Shifteh, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178696 · Cited by 13
Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond
Rajan, A., & Schrump, D. S. (2015) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2015.04.002 · Cited by 9
Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation
Lee, T., Kim, K., Lee, J., Park, S. H., Park, Y. S., Lim, H. Y., Kang, W. K., Park, J. O., & Kim, S. T. (2018) · Journal of Cancer · doi:10.7150/jca.26068 · Cited by 8
Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K ‐ras mutation
Kaseda, K., Asakura, K., Kazama, A., & Ozawa, Y. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12428 · Cited by 8
Enhancing an Oxidative “Trojan Horse” Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside
Burska, A. N., Ilyassova, B., Dildabek, A., Khamijan, M., Бегимбетова, Д., Molnár, F., & Sarbassov, D. D. (2022) · Cells · doi:10.3390/cells11213454 · Cited by 7
TargetingKRAS G12Cmutations in colorectal cancer
Zhao, M., & Wu, A. (2022) · Gastroenterology report · doi:10.1093/gastro/goac083 · Cited by 9
Cholangiocarcinoma Therapeutics: An Update
Nguyen, M. L. T., Toàn, N. L., Bożko, M., Bùi, K. C., & Bozko, P. M. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210204152028 · Cited by 8
Comprehensive multimodal and multiomic profiling reveals epigenetic and transcriptional reprogramming in lung tumors
Wu, P., Liu, Z., Zheng, L., Du, Y., Zhou, Z., Wang, W., & Lu, C. (2025) · Communications Biology · doi:10.1038/s42003-025-07954-8 · Cited by 6
RAS oncogenes direct metastasis
Σπέλλα, Μ., Marazioti, A., Arendt, K. A. M., & Stathopoulos, G. T. (2017) · Molecular & Cellular Oncology · doi:10.1080/23723556.2017.1345711 · Cited by 5
The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer
Moradi‐Marjaneh, R., Asgharzadeh, F., Khordad, E., & Marjaneh, M. M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201007163116 · Cited by 5
An Ultrasensitive FRET-based DNA Sensor via the Accumulated QD System Derivatized in the Nano-beads
Yang, L.-H., Ahn, D. J., & Koo, E. (2018) · BioChip Journal · doi:10.1007/s13206-018-2406-x · Cited by 5
CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma
Loo, S. K., Sica, G., Wang, X., Li, T., Chen, L., Gaither‐Davis, A., Huang, Y., Burns, T. F., Stabile, L. P., & Gao, S. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01307-4 · Cited by 4
An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health
Ghosh, S., Bhuniya, T., Dey, A., Koley, M., Roy, P., Bera, A., Gol, D., Chowdhury, A., Chowdhury, R., & Sen, S. (2023) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-023-04748-8 · Cited by 5
Clinical outcome of epidermal growth factor receptor‐tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutations
Zhang, H., Bai, H., Yang, X., Zhong, J., An, T., Zhao, J., & Wang, J. (2015) · Thoracic Cancer · doi:10.1111/1759-7714.12266 · Cited by 4
Discovery of Inhibitors of Protein–Protein Interactions Using Fragment‐Based Methods
Wang, F., & Fesik, S. W. (2016) · Methods and principles in medicinal chemistry · doi:10.1002/9783527683604.ch16 · Cited by 4
Evaluation of a Novel Pan-RAS Inhibitor in 3D Bioprinted Tumor Models
de Nóbrega, D. F., Eiler, L. C., Ahirwar, P., Nallapu, S., Rawal, U. P., Crawford, C. L., Buchsbaum, D. J., Keeton, A. B., Maxuitenko, Y. Y., Chen, X., et al. (2025) · Cancers · doi:10.3390/cancers17182958 · Cited by 5
Research progress of direct and indirect KRAS-targeting protein degraders in KRAS-mutant cancers
Jiang, L., Chen, Y., Zhao, J., Zhou, L., Zhou, Q., Jiang, H., Lou, D., Huang, W., & Zhang, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109161 · Cited by 4
Mechanistic insights into molecular targeted therapy and immunotherapy for lung cancer
Vincent, T., Sakthivel, K. M., Josephine, C. M. R., Prasad, R., Kathirvelan, C., Kumar, P., Saravanan, M., & Rasmi, R. R. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152204 · Cited by 3
Development of erythrina-based PARP-1/FTase dual-target inhibitors against lung cancer epithelial-mesenchymal transition (EMT) in vivo and in vitro
Yu, L., Wang, Y., Yan, Z., Zhang, L., & Li, S. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107480 · Cited by 3
Treatment of Cancers by Inhibition of Isoprenylcysteine Carboxyl Methyltransferase
Kargbo, R. B. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00269 · Cited by 3
ATP synthasome contributes to efficient energy flux in malignant breast cancer
Tzeng, Y. T., Kang, Y., Hsiao, T.-H., Chu, P.-Y., Yong, S., Lin, S.-C., Wu, M.-Y., Tseng, L., Hou, M., Wen, Z.-H., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02610-z · Cited by 2
Chromosome aberrations cause tumorigenesis through chromosomal rearrangements in a hepatocarcinogenesis rat model
Nakamura, K., Ishii, Y., Takasu, S., Namiki, M., Soma, M., Takimoto, N., Matsushita, K., Shibutani, M., & Ogawa, K. (2024) · Cancer Science · doi:10.1111/cas.16324 · Cited by 2
[Effects of farnesyltransferase silencing on the migration and invasion of tongue squamous cell carcinoma].
Sheng, S.-G., Yn, W., Wang, S.-R., Zhao, K., Yy, W., Xn, X., Qm, W., Tong, L., & Zg, C. (2020) · PubMed Central · doi:10.7518/hxkq.2020.02.012 · Cited by 2
Promising Molecular Targets for Design of Antitumor Drugs Based on Ras Protein Signaling Cascades
Klochkov, S. G., Неганова, М. Е., & Aleksandrova, Y. R. (2020) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162020050118 · Cited by 2
Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor modelsPreprint
de Nóbrega, D. F., Eiler, L. C., Ahirwar, P., Rawal, U. P., Crawford, C. L., Buchsbaum, D. J., Keeton, A. B., Maxuitenko, Y. Y., Chen, X., Piazza, G. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.25.640132 · Cited by 2
Lung cancer: Advances in diagnostic research
Pokale, R., Mukharya, A., Kudarha, R. R., Mutalik, S., Tıwarı, R., Tiwari, G., Patel, J. K., & Dhas, N. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33849-6.00015-5 · Cited by 1
Comparison between sub-lobar resection and lobar resection for clinical stage IA (tumor size ≤ 2 cm) lung invasive mucinous adenocarcinoma with tumor spread through air spaces: A multi-center real-world study
Pan, H., Kong, W., Yin, H., Shen, Y., Chen, H., Ge, Z., Li, W., Zhang, J., Tian, Y., Ning, J., et al. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.110364 · Cited by 1
KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer
Nagy, A. V., Pongor, L. S., Santarpia, M., & Győrffy, B. (2017) · European Journal of Cancer · doi:10.1016/s0959-8049(17)30657-3 · Cited by 1
Avaliação in vitro da inibição da atividade de proteínas RAS por derivados de quinolonas no modelo câncer pancreático humano
Redorat, F. S. (2017) · doi:10.26512/2017.03.d.23968 · Cited by 1
PhyloVision : Interactive Software for Integrated Analysis of Single-Cell Transcriptomic and Phylogenetic DataPreprint
Jones, M. G., Rosen, Y., & Yosef, N. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.13.460142 · Cited by 1
Adenocarcinoma of the lung: an exploration of the relationships between histopathology, molecular pathology and inflammatory markers and their relationship to patient outcomes
Clay, T. D. (2017) · Minerva Access (University of Melbourne)
Investigação das quinases Aurora A e Aurora B na tumorigenicidade mediada pelo oncogene KRAS
dos Santos, E. O. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.46.2017.tde-21062017-103949
Investigação da quinase IKKβ como um alvo terapêutico anti-metastático em câncer de pulmão associado à ativação do oncogene KRAS
Miranda, V. S. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.46.2019.tde-01082019-085027
Molecular mechanisms of lung cancer
Лосев, О. Э., Бородулин, В. Б., Юрьевна, Р. Н., Бобылева, Е. В., & Владимирович, Б. Я. (2021) · Zhurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia» · doi:10.25557/0031-2991.2021.01.124-132
ERO1α Promotes Tumorigenesis in EGFR Driven NSCLC
Johnson, B. D. (2022) · doi:10.33915/etd.11621

Authors: Vasan, N., Boyer, J. L., & Herbst, R. S.
Affiliations: Massachusetts General Hospital (US)
Cornell University (US)
Yale Cancer Center (US)
Corresponding author: Herbst, Roy S.
ORCID: Vasan, Neil
Herbst, Roy S.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2014-07-31
Volume: 20
Issue: 15
Pages: 3921-3930
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-13-1762
PMC: PMC5369356
OpenAlex: W1982288880
Cited by: 102
References: 79
Citations by year: 2026: 3 · 2025: 8 · 2024: 5 · 2023: 3 · 2022: 8 · 2021: 6 · 2020: 7 · 2019: 9 · 2018: 10 · 2017: 14 · 2016: 13 · 2015: 14 · 2014: 2
FWCI: 1.35
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA155196)
National Institute of General Medical Sciences (T32GM007205)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords: KRAS mutation, non-small cell lung cancer, oncogenic Ras, targeted therapy, Ras signaling, farnesyltransferase inhibitors, RCE1, IcmT, PDEδ, synthetic lethality, siRNA screen, RAS-driven cancers
MeSH terms: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Prognosis, Proto-Oncogene Proteins, Signal Transduction, Proto-Oncogene Proteins p21(ras), ras Proteins, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks